Adverum Biotechnologies Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Adverum Biotechnologies Inc 's ROA in the third quarter of 2025?
Adverum Biotechnologies Inc recorded a cumulative net loss of $-204 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -168.9%.

However, within the Healthcare sector 850 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2025 from 4518 to 4555.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-68.02 %	-60.98 %	-48.82 %	-1.95 %	15.99 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-204	-189	-170	-151	-114
Return On Assets (TTM)	-168.9 %	-118.56 %	-86.47 %	-65.55 %	-49.33 %
ADVM's Total Ranking	# 4555	# 4518	# 4471	# 5009	# 4299
Total Assets (TTM) in million	72	96	137	179	226
Seq. Total Assets Change	-24.75 %	-29.59 %	-23.65 %	-20.94 %	-8.18 %
Seq. Net Income Change	-	-	-	-	-

ADVM's 5 Years Annual ROA >> Back to ADVM Management Effectiveness >> Compare ADVM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 131
Sector	# 851
Overall	# 4500

Return On Assets Statistics
High	Average	Low
21.18 %	-38.86 %	-168.2 %
(Dec 31 2014)		(Sep 30 2025)

Financial Statements
Adverum Biotechnologies Inc 's Assets	$ 72 million	ADVM's Balance sheet
Adverum Biotechnologies Inc 's Income	$ -48 million	Quarterly ADVM's Income Statement
ADVM's Income by Division		See ADVM's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	3.41 %	-43.74 %	-29.74 %	-8.35 %	114.41 %
Total Assets in million	179	173	308	438	478
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-131	-117	-155	-146	-118
Annual Return On Assets	-73.18 %	-67.72 %	-50.25 %	-33.25 %	-24.61 %

ADVM's 5 Years Annual ROA >> Back to ADVM Management Effectiveness >> Compare ADVM ROA to its Competitors

More Return On Assets Ratios
ADVM's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADVM's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADVM's Competitors
Subscribers only: Roa for Adverum Biotechnologies Inc 's Suppliers
Subscribers only: Return On Assets for ADVM's Customers

You may also want to know
ADVM's Roi	ADVM's Inventory Turnover Ratio	ADVM's Growth Rates	ADVM's Dividend Comparisons
	ADVM's Profitability Ratios	ADVM's Asset Turnover Ratio	ADVM's Dividend Growth
ADVM's Roe	ADVM's Valuation Ratios	ADVM's Financial Strength Ratios	ADVM's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:23:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.